Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback